Clinical Trial

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

Study acronym: IRAK4
Suspended Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 22, 2026 (before its estimated June 18, 2026 completion). Its status may not reflect the trial's current state.
Why the trial stopped
Safety issue was identified in the Phase2b D7860C00006 study, evaluating AZD6793 in moderate to very severe COPD participants. D7860C00005 study is temporary halted to amend the design to reflect changes implemented in the ongoing D7860C00006 study
Summary
The purpose of this study is to examine the effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus.
Protocol Amendment History 1 change
critical Recruitment suspended 2026-04-23
Trial Details
NCT Number NCT07433062
Lead Sponsor AstraZeneca
Conditions Type 2 Diabetes Mellitus
Enrollment 28 participants
Start Date 2026-01-14
Primary Completion 2026-06-18 (estimated)
Study Completion 2026-06-18 (estimated)
Updated on ClinicalTrials.gov 2026-04-22